Nano Today, volume 42, pages 101350

Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics

Eugene Marfo Obeng 1
Christian K O Dzuvor 2
Xianhai Zeng 3
Publication typeJournal Article
Publication date2022-02-01
Journal: Nano Today
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor17.4
ISSN17480132
Pharmaceutical Science
Biotechnology
General Materials Science
Bioengineering
Biomedical Engineering
Abstract
In the past two decades, the emergence of coronavirus diseases has been dire distress on both continental and global fronts and has resulted in the search for potent treatment strategies. One crucial challenge in this search is the recurrent mutations in the causative virus spike protein, which lead to viral escape issues. Among the current promising therapeutic discoveries is the use of nanobodies and nanobody-like molecules. While these nanobodies have demonstrated high-affinity interaction with the virus, the unpredictable spike mutations have warranted the need for avidity-inspired therapeutics of potent inhibitors such as nanobodies. This article discusses novel approaches for the design of anti-SARS-CoV-1 and -2 nanobodies to facilitate advanced innovations in treatment technologies. It further discusses molecular interactions and suggests multivalent protein nanotechnology and chemistry approaches to translate mere molecular affinity into avidity.

Top-30

Citations by journals

1
2
3
International Journal of Molecular Sciences
3 publications, 20%
Small Methods
1 publication, 6.67%
Journal of Materials Science and Technology
1 publication, 6.67%
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
1 publication, 6.67%
Cancer Communications
1 publication, 6.67%
ACS Applied Bio Materials
1 publication, 6.67%
Science advances
1 publication, 6.67%
Talanta
1 publication, 6.67%
Virology
1 publication, 6.67%
Advanced Science
1 publication, 6.67%
International Journal of Biological Macromolecules
1 publication, 6.67%
PLoS Pathogens
1 publication, 6.67%
Russian Chemical Reviews
1 publication, 6.67%
1
2
3

Citations by publishers

1
2
3
Multidisciplinary Digital Publishing Institute (MDPI)
3 publications, 20%
Wiley
3 publications, 20%
Elsevier
3 publications, 20%
Springer Nature
2 publications, 13.33%
American Chemical Society (ACS)
1 publication, 6.67%
American Association for the Advancement of Science (AAAS)
1 publication, 6.67%
Public Library of Science (PLoS)
1 publication, 6.67%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.67%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Obeng E. M., Dzuvor C. K. O., Zeng X. Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics // Nano Today. 2022. Vol. 42. p. 101350.
GOST all authors (up to 50) Copy
Obeng E. M., Dzuvor C. K. O., Zeng X. Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics // Nano Today. 2022. Vol. 42. p. 101350.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.nantod.2021.101350
UR - https://doi.org/10.1016/j.nantod.2021.101350
TI - Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
T2 - Nano Today
AU - Obeng, Eugene Marfo
AU - Dzuvor, Christian K O
AU - Zeng, Xianhai
PY - 2022
DA - 2022/02/01 00:00:00
PB - Elsevier
SP - 101350
VL - 42
SN - 1748-0132
ER -
BibTex
Cite this
BibTex Copy
@article{2022_Obeng,
author = {Eugene Marfo Obeng and Christian K O Dzuvor and Xianhai Zeng},
title = {Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics},
journal = {Nano Today},
year = {2022},
volume = {42},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/j.nantod.2021.101350},
pages = {101350},
doi = {10.1016/j.nantod.2021.101350}
}
Found error?